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Objectives. The ability of a probiotic Lactobacillus rhamnosus strain (Lcr35) to adhere to cervical and vaginal cells and to aﬀect
the viability of two main vaginosis-associated pathogens, Prevotella bivia, Gardnerella vaginalis,a sw e l la sCandida albicans was
investigated. Methods. Adhesion ability was determined in vitro with immortalized epithelial cells from the endocervix, ectocervix,
andvagina.CocultureexperimentswereperformedtocountviablepathogenscellsinthepresenceofLcr35. Results.Lcr35wasable
to speciﬁcally and rapidly adhere to the three cell lines. In coculture assays, a decrease in pathogen cell division rate was observed
as from 4 hours of incubation and bactericidal activity after a longer period of incubation, mostly with P. bivia. Conclusion.T h e
ability of Lcr35 to adhere to cervicovaginal cells and its antagonist activities against vaginosis-associated pathogens suggest that
this probiotic strain is a promising candidate for use in therapy.
Copyright © 2008 Sophie Coudeyras et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Bacterial vaginosis (BV) is the most frequent vaginal
infectious disorder in women of childbearing age with
prevalences ranging from 10% to 50% [1]. In addition
to the physiological burden that induces BV, it can cause
serious sequelae such as preterm birth and facilitate the
acquisition of sexually transmitted diseases. The cause of BV
remains poorly understood, and no speciﬁc infectious agents
have been identiﬁed. However, the disorder is characterized
by modiﬁcations of the genital tract microﬂora, including
a reduction in or absence of lactobacillus colonization
and overgrowth of several anaerobic bacteria [2]. The
vaginal ecosystem in healthy premenopausal women harbors
a microbiota dominated by Lactobacilli [3, 4], that is,
being increasingly recognized as protecting it from invading
pathogens,includingthosethatcauseurinarytractinfections
and sexually transmitted diseases. Diﬀerent mechanisms are
potentially involved in the activity of Lactobacilli against
pathogens, including the competitive exclusion of genitouri-
nary pathogens from receptors present on the surface of the
epithelialcells.Underhealthyconditions,cervicovaginalcells
are constantly exposed to the normal vaginal microbiota.
The recommended treatment regimens for vaginal infec-
tions are oral or intravaginal antibiotics [5], but these
conventional treatments are associated with frequent recur-
rences. Alternative therapeutic agents need to be sought, and
it has been suggested that the administration of Lactobacilli
can restore ecological balance in the vagina by controlling
the infectivity of pathogenic microbes [3], but the treatment
is still a subject of debate. Several clinical trials have been
performed to investigate the eﬀects of speciﬁc strains, mainly
with L. acidophilus and L. rhamnosus species [6, 7], but
no deﬁnitive conclusions as to whether these probiotics
represent an eﬀective and safe method for treating women
with BV can be drawn. The behavior of the probiotics in the
vaginal tract is likely to be strain speciﬁc and therefore, it is
important to determine the characteristics of the strain to
be used as a therapeutic agent. The most relevant properties
in this context are likely to be adhesion to cervicovaginal
cells and adequate pathogen growth inhibition. In vitro
studies assessing these properties might not be able to fully2 Infectious Diseases in Obstetrics and Gynecology
simulate the in vivo behavior, but they could be reliable
indicators when selecting the probiotic strain. The purpose
of this study was to determine the in vitro adherence of
a well characterized L. rhamnosus probiotic strain, Lcr35
[8–10], and its ability to inhibit growth of three vaginosis-
associated pathogens. We used immortalized morpholog-
ically and functionally distinct epithelial cell lines from
normal endocervix, ectocervix, and vagina to characterize
Lcr35 epithelial interactions pertinent to the lower female
genitaltractanddetermineditsantimicrobialactivityagainst
Prevotella bivia, Gardnerella vaginalis,a n dCandida albicans
in coculture experiments.
2. MATERIALS AND METHODS
2.1. Adhesionassay
Adhesion assays were performed with epithelial cells
from normal human vagina (VK2/E6E7 ATCC-CRL-2616),
ectocervix (Ect1/E6E7 ATCC-CRL-2614), and endocervix
(End1/E6E7 ATCC-CRL-2615), immortalized by expression
of the E6 and E7 genes of human papillomavirus type 16
[11]. The morphological and immunocytochemical charac-
teristics of the immortalized lines closely resembled those of
their tissues of origin and primary cultures and are likely to
represent the diﬀerent compartments of the vaginal tract.
The cell lines were maintained in keratinocyte serum-
free medium (Gifco BRL 17005-042) supplemented with
human recombinant EGF (0.1ng/mL), bovine pituitary
extract (0.05mg/mL), and calcium chloride (0.4mM) at
37
◦C with a 5% CO2 in air atmosphere.
Adhesion of the Lcr35 was assayed by seeding cell
lines in 24-well tissue culture plates at 2.5 × 105 epithelial
cells/well and allowing them to grow to complete conﬂuence
(105 cells/well). After gentle washing of the cell monolayer,
the adhesion capacity of Lcr35 was determined by adding
105multiplicity of infection (MOI,1), 106 (MOI, 10), and
107 (MOI, 100) bacteria from an overnight culture in de
Man, Rogosa, Sharpe (MRS) agar medium. Bacterial cells
were previously washed in phosphate buﬀered saline and
resuspended in the cell culture medium. Adhesion was
monitored after 1 and 3 hours of incubation carried out at
37
◦C under 5% CO2. The monolayers were washed three
times with 1mL of Dulbecco’s phosphate buﬀered saline,
detached by addition of 0.1% TritonX-100 solution and
the number of viable bacteria determined by plating serial
dilutions of the suspensions onto MRS agar plates. For
qualitativeanalysis,thecellmonolayersandthebacteriawere
methanol ﬁxed and stained by addition of a 10% Giemsa
solution.
2.2. Growthinhibitionof
vaginosis-associatedpathogens
The eﬀect of Lcr35 on the growth of three pathogens was
investigated using the following strains: Candida albicans
ATCC10231, Prevotella bivia ATCC29303, and Gardnerella
vaginalis ATCC14018. Coculture assays were performed in
either Sabouraud broth (Candida) or brain heart infusion
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Figure 1: Adherence of L. rhamnosus Lcr35 to vaginal, ecto-
and endocervical cells. Epithelial cells were incubated with three
diﬀerent bacterial inocula and incubated for 1 hour. The number of
viable Lcr35 adhering to the cell monolayer surface was determined
by plating onto appropriate media. The data are averages of
three independent experiments performed in triplicate. Error bars
indicate standard deviations.
supplemented with yeast extract (1%), maltose (0.1%),
glucose (0.1%), and horse serum (10%) (Prevotella and
Gardnerella). Each pathogen (108 UFC) was incubated alone
(control) and with the Lcr35 (108 UFC) at 37
◦Cu n d e r
anaerobic conditions for the two vaginosis-associated bac-
teria (AnaeroGen, Oxo¨ ıd). Aliquots were removed after 4,
8, and 24 hours of incubation, serially diluted and plated
on appropriate media (Sabouraud, Gardnerella, or MRS) to
determine the bacterial colony counts of both the pathogens
and Lcr35. Statistical analyses of the data were performed
using the Mann-Whitney test.
3. RESULTS
3.1. AdhesionofLcr35tocervicalandvaginalcells
The ability of Lcr35 to adhere to vaginal and cervical
cells is shown in Figure 1. Whatever the MOI and the cell
line, the probiotic strain was able to adhere to the cell
surface monolayer. The highest number of adherent bacteria
was observed with the vaginal cell line, with an average
of 4.75 10e5 CFU per cm2 after 1 hour of incubation.
No major diﬀerence was observed between the levels of
adhesion obtained after 1 hour and 3 hours of incubation
(data not shown), suggesting that adhesion occurs rapidly
after the initial contact between the cells and the bacteria.
Microscopical observations of Giemsa-stained preparation
showed typical chains of Lcr35 randomly dispersed on the
cell surface (Figure 2).
3.2. Growthinhibitionof
vaginosis-associatedpathogens
The antagonist eﬀect of Lcr35 against three main pathogens,
P. bivia, G. vaginalis,a n dC. albicans, was assessed in
coculture assays and compared with the growth ability of
each pathogen in the same culture medium (Figure 3). A
decrease in the cell division rate of the three microorganismsSophie Coudeyras et al. 3
(a)
(b)
Figure 2: Giemsa-stains from adherence assays performed for the
experiment shown in Figure 1 with (a) vaginal and (b) ectocervical
cells.
tested was observed from 4 hours of coincubation. When the
viable bacteria in the mixed suspension were counted over
a longer period of time, bactericidal activity was detected
between 8 and 24 hours of incubation for all pathogens with
thePrevotellastrainbeingthemostsusceptible(4-log10units
decrease in the number of viable cells). In no case there was
a bactericidal eﬀect against Lactobacilli; the number of viable
Lcr35 cells was either constant over the incubation period
(coculture with C. albicans) or increased (coculture with G.
vaginalis and P. bivia) (data not shown).
4. DISCUSSION
Lactobacillus species in the female urogenital system act as
a barrier to infection and contribute to the control of the
vaginalmicrobiotabycompetingwithothermicroorganisms
for adherence to epithelial cells, displacing pathogen bioﬁlm
[12, 13], and/or inhibiting the growth of potential pathogens
[14–16]. Hence the use of probiotic strains of Lactobacilli is
potentiallyinterestingbothaspreventiveandcurativeagents.
Unlike the use of vaginal epithelial cells collected from
healthy premenopausal women, assays performed with
immortalized epithelial cell lines, which closely resemble
the epithelial diﬀerentiation patterns of normal human
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Figure 3: Eﬀect of Lcr35 on the viability of Prevotella bivia (a),
Gardnerella vaginalis (b), and Candida albicans (c) as a function of
the time of coculture. The pathogen was incubated without (ﬁlled
s q u a r e )o rw i t h( e m p t ys q u a r e s )L c r 3 5a t3 7
◦C for 24 hours and the
colony forming unit mL
−1 was determined after 4, 8, and 24 hours
of incubation by plating onto appropriate media. Each value shown
isthemean ±SDfromthreeexperiments. ∗ :statisticallysigniﬁcant
diﬀerences (P = .050, Mann-Whitney test).4 Infectious Diseases in Obstetrics and Gynecology
tissues, are more accurate for standardizing tested bacte-
rial adherence and allow comparison of diﬀerent research
approaches. The three epithelial cell lines tested in this study
were developed from normal human vagina, ectocervix, and
endocervix tissue, and their characteristics closely resembled
those of their tissues of origin and primary cultures [11].
We can thus speculate that adhesion assays performed with
this material reproduce more faithfully the in vivo situation
than experiments performed with any cell line derived from
human carcinoma of the lower genital tract mucosa. This
is particularly important when comparing bacterial strains
belonging to the complex Lactobacillus genus that includes
bacterial strains with highly speciﬁc characteristics. Using
these cell lines, we observed speciﬁc adhesion of an L.
rhamnosus strain, Lcr35, previously selected for its probiotic
features [8–10]. Adhesion occurred even at a low MOI (1:1)
and within less than 1 hour of contact, which corresponds to
a highly dynamic process.
Adhesion of Lcr35 to vaginal epithelial cells would allow
colonization of the vaginal mucosa and therefore could limit
the overgrowth of pathogens, but the second main property
of a potential probiotic used as a therapeutic agent against
pathogenic microorganisms is direct impairment of their
growth. In this study, we demonstrated that Lcr35 showed
bactericidal activity against both P. bivia and G. vaginalis in
the range of killing stipulated for the bactericidal activity
of antimicrobial activity (>2 log-unit). In a previous study,
Atassi et al. demonstrated that the bactericidal activity of
Lactobacilli toward these two vaginal bacterial pathogens
was strain dependent and occurred within the ﬁrst hours
of coculture [14]. In our experiments, a longer incubation
time was required to observe bactericidal activity, probably
because of the diﬀerent experimental parameters used in
the two assays. We previously showed that the Lcr35
probiotic strain was also able to kill several pathogens [10].
The mechanism(s) underlying this activity has not been
elucidated but is likely to be multifaceted and probably
includes the production of hydrogen peroxide, lactic acid,
and antibacterial compounds. It has been recently shown
that G. vaginalis organized in bioﬁlms is more resistant
to H2O2 and lactic acid than planktonic cultures [17].
G. vaginalis is the predominant species observed within
bioﬁlms present on the vaginal epithelium in bacterial
vaginosis [18], and Saunders et al. recently showed that
strains of Lactobacilli were able to disrupt G. vaginalis
preformed bioﬁlms [13]. It would therefore be interesting
to test the bioﬁlm activity of Lcr35 against G. vaginalis
and to determine if the sessile form of Lcr35 also exhibits
antibacterial activity against G. vaginalis in mixed bioﬁlm
assays.
The antagonist activity of Lcr35 was not limited to
bacterial pathogens since the strain was also able to reduce
the viability of C. albicans. Several strains of Lactobacilli have
shown inhibitory eﬀects against C. albicans [16], which is the
species most often associated with candidiasis. By interfering
withCandidaovergrowthinthepatients’intestinalorvaginal
tract, Lactobacilli could provide colonization resistance and
maintain low numbers of yeasts, especially when adminis-
tered together with antibiotics.
Relevant clinical trials have suggested that intravaginal or
oral administration of Lactobacillus strains is able to increase
the numbers of vaginal Lactobacilli and restore the vaginal
microbiota to normal [7]. Lcr35 was isolated from a human
intestinal and not vaginal microbiota and does not belong
to the four main species of Lactobacilli considered to be
predominantly linked to the vaginal microﬂora, L. crispatus,
L. jensenii, L. gasseri,a n dL. iners [4, 19, 20], but it has been
shown to survive within the human gastrointestinal tract
[9]. Furthermore, Petricevic and Witt recently showed in a
clinical study that topical administration of Lcr35 enhances
the restoration of the vaginal ﬂora after antibiotic treatment
of BV [21]. Thus, it might be an excellent candidate for use
as a prophylactic agent, taken orally or applied topically. In
vivo studies to evaluate its feasibility as such are in progress.
5. CONCLUSION
Maintenance or reconstruction of the normal composition
of the vaginal microﬂora by applying properly selected
Lactobacilli may be of prophylactic value in preventing or
curing genitourinary system infections in women. In the
light of our experiments, it seems that the probiotic strain L.
rhamnosus Lcr35 would be a good candidate as a protective
agent against both bacterial vaginosis and Candida vaginitis
since it was able to adhere to vaginal and cervical cells and
to antagonist the growth of vaginosis-associated pathogens.
Clinical studies are now required to assess the in vivo eﬃcacy
of such a therapy.
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